Cargando…
A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
In this review, we collected 1765 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) M-pro inhibitors from the bibliography and other sources, such as the COVID Moonshot project and the ChEMBL database. This set of inhibitors includes only those compounds whose inhibitory capacity, mainly...
Autores principales: | Macip, Guillem, Garcia-Segura, Pol, Mestres-Truyol, Júlia, Saldivar-Espinoza, Bryan, Pujadas, Gerard, Garcia-Vallvé, Santiago |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745775/ https://www.ncbi.nlm.nih.gov/pubmed/35008685 http://dx.doi.org/10.3390/ijms23010259 |
Ejemplares similares
-
Haste makes waste: A critical review of docking‐based virtual screening in drug repurposing for SARS‐CoV‐2 main protease (M‐pro) inhibition
por: Macip, Guillem, et al.
Publicado: (2021) -
Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition
por: Gimeno, Aleix, et al.
Publicado: (2020) -
Prediction of Recurrent Mutations in SARS-CoV-2 Using Artificial Neural Networks
por: Saldivar-Espinoza, Bryan, et al.
Publicado: (2022) -
Could nucleocapsid be a next-generation COVID-19 vaccine candidate?
por: Saldivar-Espinoza, Bryan, et al.
Publicado: (2022) -
The Mutational Landscape of SARS-CoV-2
por: Saldivar-Espinoza, Bryan, et al.
Publicado: (2023)